Fetomaternal alloimmune thrombocytopenia: The questions that still remain

References

• Davoren A, Curtis B R, Aster R H, McFarland J G. Human platelet antigen-specific alloantibodies implicated in 1162 cases of neonatal alloimmune thrombocytopenia. Transfusion 2004; 44: 1220–1225
   PubMed Web of Science ®Google Scholar
• Dreyfus M, Kaplan C, Verdy E, Schlegel N, Durand-Zaleski I, Tchernia G. Frequency of immune thrombocytopenia in newborns: A prospective study. Immune thrombocytopenia working group. Blood 1997; 89: 4402–4406
   PubMed Web of Science ®Google Scholar
• Kim H O, Jin Y, Kickler T S, Blakemore K, Kwon O H, Bray P F. Gene frequencies of the five major human platelet antigens in African American, white, and Korean populations. Transfusion 1995; 35: 863–867
   PubMed Web of Science ®Google Scholar
• Ghevaert C, Campbell K, Walton J, Smith G A, Allen D, Williamson L M, Ouwehand W H, Ranasinghe E. Management and outcome of 200 cases of fetomaternal alloimmune thrombocytopenia. Transfusion 2007; 47: 901–910
   PubMed Web of Science ®Google Scholar
• Blanchette V S, Johnson J, Rand M. The management of alloimmune neonatal thrombocytopenia. Baillieres Best Pract Res Clin Haematol 2000; 13: 365–390
   PubMedGoogle Scholar
• Campbell-Lee S A, DeSantis-Parsons D, Shirey R S, Kickler T S. Neonatal alloimmune thrombocytopenia due to anti-HPA-5b (bra). Immunohematol 2003; 19: 127–131
   PubMedGoogle Scholar
• Turner M L, Bessos H, Fagge T, Harkness M, Rentoul F, Seymour J, Wilson D, Gray I, Ridheesh A, Cairns J, Urbaniak S. Prospective epidemiologic study of the outcome and cost-effectiveness of antenatal screening to detect neonatal alloimmune thrombocytopenia due to anti-HPA-1a. Transfusion 2005; 45: 1945–1956
   PubMed Web of Science ®Google Scholar
• Ahya R, Turner M L, Urbaniak S J, SNAIT study team. Fetomaternal alloimmune thrombocytopenia. Transfus Apher Sci 2001; 25: 139–145
   PubMed Web of Science ®Google Scholar
• Williamson L M, Hackett G, Rennie J, Palmer C R, Maciver C, Hadfield R, Hughes D, Jobson S, Ouwehand W H. The natural history of fetomaternal alloimmunization to the platelet-specific antigen HPA-1a (PlA1, zwa) as determined by antenatal screening. Blood 1998; 92: 2280–2287
   PubMed Web of Science ®Google Scholar
• Radder C M, Brand A, Kanhai H H. A less invasive treatment strategy to prevent intracranial hemorrhage in fetal and neonatal alloimmune thrombocytopenia. Am J Obstet Gynecol 2001; 185: 683–688
   PubMedGoogle Scholar
• Murphy M F, Williamson L M, Urbaniak S J. Antenatal screening for fetomaternal alloimmune thrombocytopenia: Should we be doing it?. Vox Sang 2002; 83(Suppl 1)409–416
   PubMedGoogle Scholar
• Bussel J B, Berkowitz R L, McFarland J G, Lynch L, Chitkara U. Antenatal treatment of neonatal alloimmune thrombocytopenia. N Engl J Med 1988; 319: 1374–1378
   PubMed Web of Science ®Google Scholar
• Silver R M, Porter T F, Branch D W, Esplin M S, Scott J R. Neonatal alloimmune thrombocytopenia: Antenatal management. Am J Obstet Gynecol 2000; 182: 1233–1238
   PubMed Web of Science ®Google Scholar
• Bowman J, Harman C, Mentigolou S, Pollock J. Intravenous fetal transfusion of immunoglobulin for alloimmune thrombocytopenia. Lancet 1992; 340: 1034–1035
   PubMedGoogle Scholar
• Weiner E, Zosmer N, Bajoria R, Sepulveda W, Vaughan J I, Letsky E A, Fisk N M. Direct fetal administration of immunoglobulins: Another disappointing therapy in alloimmune thrombocytopenia. Fetal Diagn Ther 1994; 9: 159–164
   PubMedGoogle Scholar
• van den Akker E, Oepkes D, Lopriore E, Brand A, Kanhai H. Noninvasive antenatal management of fetal and neonatal alloimmune thrombocytopenia: Safe and effective. BJOG 2007; 114: 469–473
   PubMed Web of Science ®Google Scholar
• Murphy M F, Bussel J B. Advances in the management of alloimmune thrombocytopenia. Br J Haematol 2007; 136: 366–378
   PubMedGoogle Scholar
• Bussel J B, Berkowitz R L, Lynch L, Lesser M L, Paidas M J, Huang C L, McFarland J G. Antenatal management of alloimmune thrombocytopenia with intravenous gamma-globulin: A randomized trial of the addition of low-dose steroid to intravenous gamma-globulin. Am J Obstet Gynecol 1996; 174: 1414–1423
   PubMed Web of Science ®Google Scholar
• Berkowitz R L, Kolb E A, McFarland J G, Wissert M, Primani A, Lesser M, Bussel J B. Parallel randomized trials of risk-based therapy for fetal alloimmune thrombocytopenia. Obstet Gynecol 2006; 107: 91–96
   PubMed Web of Science ®Google Scholar
• Althaus J, Weir E G, Askin F, Kickler T S, Blakemore K. Chronic villitis in untreated neonatal alloimmune thrombocytopenia: An etiology for severe early IUGR and the effect of intravenous immunoglobulin therapy. Am J Obstet Gynecol 2005; 193(3 Pt 2)1100–1104
   PubMedGoogle Scholar
• Overton T G, Duncan K R, Jolly M, Letsky E, Fisk N M. Serial aggressive platelet transfusion for fetal alloimmune thrombocytopenia: Platelet dynamics and perinatal outcome. Am J Obstet Gynecol 2002; 186: 826–831
   PubMed Web of Science ®Google Scholar
• Radder C M, Brand A, Kanhai H H. Will it ever be possible to balance the risk of intracranial haemorrhage in fetal or neonatal alloimmune thrombocytopenia against the risk of treatment strategies to prevent it?. Vox Sang 2003; 84: 318–325
   PubMed Web of Science ®Google Scholar
• Aina-Mumuney A, Holcroft C J, Bienstock J L, Milio L, Crino J, Blakemore K J. Fetal intrahepatic vein sampling: The procedure of choice for fetal thrombocytopenia?. Am J Obstet Gynecol 2003; 189(S228)619
   Google Scholar
• Nicolini U, Nicolaidis P, Fisk N M, Tannirandorn Y, Rodeck C H. Fetal blood sampling from the intrahepatic vein: Analysis of safety and clinical experience with 214 procedures. Obstet Gynecol 1990; 76: 47–53
   PubMedGoogle Scholar
• Tiblad E, Olsson I, Petersson K, Shanwell A, Winiarski J, Wolff K, Westgren M. Experiences with fetomaternal alloimmune thrombocytopenia at a Swedish hospital over a 10-year period. Acta Obstet Gynecol Scand 2003; 82: 803–806
   PubMedGoogle Scholar
• Kanhai H H, van den Akker E S, Walther F J, Brand A. Intravenous immunoglobulins without initial and follow-up cordocentesis in alloimmune fetal and neonatal thrombocytopenia at high risk for intracranial hemorrhage. Fetal Diagn Ther 2006; 21: 55–60
   PubMedGoogle Scholar
• Kjeldsen-Kragh J, Killie M K, Tomter G, Golebiowska E, Randen I, Hauge R, Oian P, Lauritz B D, Pirhonen J, Lindeman R, Husby H, Haugen G, Gronn M, Skogen B, Husebekk A. A screening and intervention program aimed to reduce mortality and serious morbidity associated with severe neonatal alloimmune thrombocytopenia, Blood First Edition Paper, prepublished online April 11, 2007. DOI: 10.1182/blood-2006-08-040121
   Google Scholar
• Killie M K, Kjeldsen-Kragh J, Husebekk A, Skogen B, Olsen J A, Kristiansen I S. Cost-effectiveness of antenatal screening for neonatal alloimmune thrombocytopenia. BJOG 2007; 114: 588–595
   PubMedGoogle Scholar